[Skip to Navigation]
Invited Commentary
February 2016

Can Patient Risk Factors Outperform Antiemetic Guidelines?Choosing Wisely

Author Affiliations
  • 1Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, Ontario, Canada
  • 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
  • 3Department of Pharmacy, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
  • 4Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
JAMA Oncol. 2016;2(2):232-233. doi:10.1001/jamaoncol.2015.3757

In 2013 as part of its Choosing Wisely initiative,1 the American Society of Clinical Oncology (ASCO) recommended reserving relatively expensive antiemetics, eg, neurokinin1 receptor antagonists (NK1 RAs), for patients who were at high risk for emesis. ASCO classifies chemotherapy containing an anthracycline and cyclophosphamide (AC) as highly emetogenic, and thus an NK1 RA is recommended with AC treatments. Clemons and colleagues2 have tried to take this advice a step further with a risk-managed approach to antiemetics in women receiving AC in a setting where usual practice did not conform to ASCO guidelines.

×